Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection

Gastroenterology. 2007 Nov;133(5):1627-36. doi: 10.1053/j.gastro.2007.08.003. Epub 2007 Aug 2.

Abstract

Background & aims: Persistent inflammation contributes to progression of liver damage in chronic HCV (cHCV) infection. Repeated exposure to toll-like receptor (TLR) ligands results in tolerance, a protective mechanism aimed at limiting inflammation.

Methods: Monocytes/macrophages were repeatedly stimulated via proinflammatory cytokine-inducing TLRs and evaluated for activation markers.

Results: Unlike monocytes of controls or patients with nonalcoholic steatohepatitis, the monocytes of cHCV patients were hyperresponsive and failed to show homo- or heterotolerance to TLR ligands, manifested by elevated tumor necrosis factor (TNF)-alpha production. Serum levels of interferon (IFN)-gamma, endotoxin (TLR4 ligand), and HCV core protein (TLR2 ligand) were elevated in cHCV patients suggesting potential mechanisms for in vivo monocyte preactivation. Treatment of normal monocytes with IFN-gamma resulted in loss of tolerance to lipopolysaccharide (LPS) or HCV core protein. Furthermore, we found increased levels of MyD88-IRAK1 complexes and nuclear factor (NF)-kappaB activity both in monocytes of cHCV patients and in normal monocytes that lost TLR tolerance after IFN-gamma + LPS pretreatment. In vitro differentiation of TLR non-tolerant cHCV monocytes into macrophages restored their capacity to exhibit TLR tolerance to LPS and HCV core protein, and this could be reversed by administration of IFN-gamma. cHCV patients exhibited increased TNF-alpha in the circulation and in the liver. In cHCV livers, we found Kupffer cell/macrophage activation indicated by increased CD163 and CD33 expression.

Conclusions: We identified that host-derived factors (IFN-gamma and endotoxin) and viral factors (HCV core protein) act in tandem to induce and maintain monocyte/macrophage activation, thus favoring persistent inflammation in patients with cHCV infection.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Case-Control Studies
  • Endotoxins / blood
  • Endotoxins / pharmacology*
  • Female
  • Hepacivirus / metabolism
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / immunology*
  • Humans
  • Inflammation / metabolism
  • Inflammation / pathology
  • Interferon-gamma / blood
  • Interferon-gamma / pharmacology*
  • Kupffer Cells / drug effects
  • Kupffer Cells / metabolism
  • Kupffer Cells / pathology
  • Ligands
  • Lipopolysaccharides / pharmacology
  • Macrophage Activation / drug effects*
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Macrophages / pathology
  • Male
  • Middle Aged
  • Monocytes / drug effects
  • Monocytes / metabolism
  • Monocytes / pathology
  • NF-kappa B / metabolism
  • Toll-Like Receptor 2 / blood
  • Toll-Like Receptor 4 / blood
  • Toll-Like Receptors / immunology*
  • Tumor Necrosis Factor-alpha / metabolism
  • Viral Core Proteins / blood
  • Viral Core Proteins / pharmacology*

Substances

  • Endotoxins
  • Ligands
  • Lipopolysaccharides
  • NF-kappa B
  • TLR2 protein, human
  • TLR4 protein, human
  • Toll-Like Receptor 2
  • Toll-Like Receptor 4
  • Toll-Like Receptors
  • Tumor Necrosis Factor-alpha
  • Viral Core Proteins
  • Interferon-gamma